ReviewNature reviews. Drug discovery2021
Engineering islets from stem cells for advanced therapies of diabetes.
Review in Nature reviews. Drug discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 124 citations in OpenAlex.
- Charting Endocrine Progenitors Across Species and Organs.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Resolving human α versus β cell fate allocation for the generation of stem cell-derived islets.Nature communications · 2026Article
- Multi-omics profiling implicates gut microbiota-sphingolipid interplay in the neuroprotective effects of semaglutide on diabetic cognitive impairment.Frontiers in microbiology · 2026Article
- Associations of Inflammatory Prognosis Index With All-Cause and Cardiovascular Mortality Among Individuals With Diabetes and Prediabetes: A Retrospective Cohort Study.Mediators of inflammation · 2026Article
- Gingival mesenchymal stem cell-derived exosomal miR-23a-3p targets IL-6R to attenuate autoimmune insulitis: a cell-free therapeutic strategy for type 1 diabetes.Stem cell research & therapy · 2025Article
- Engineering hypoimmune stem cell-derived beta cells.Stem cell research & therapy · 2025Review
- Single-cell transcriptome analysis ofGenes & diseases · 2025Article
- A multimodal cross-species comparison of pancreas development.Nature communications · 2025Article
- Autoimmune Type 1 Diabetes in the Era of Disease-Modifying Immune Therapy.Diabetes/metabolism research and reviews · 2025Review
- Exendin-4 enhances insulin-positive phenotype of human pluripotent stem cell-derived β cells during transplantation.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Advancements in photobiomodulation for generating functional beta cells from adipose derived stem cells in 3D culture: a comprehensive review.Stem cell research & therapy · 2025Review
- Engineering Cell Fate with Adaptive Feedback Control.ACS synthetic biology · 2025Article
- Improving cellular fitness of human stem cell-derived islets under hypoxia.Nature communications · 2025Article
- The Diurnal Variation in Mitochondrial Gene in Human Type 2 Diabetic Mesenchymal Stem Cell Grafts.International journal of molecular sciences · 2025Article
- Application of Ultrasound Localization Microscopy in Evaluating the Type 2 Diabetes Progression.Cyborg and bionic systems (Washington, D.C.) · 2025Article
- The Application of Nanomaterials in the Treatment of Pancreatic-Related Diseases.International journal of molecular sciences · 2024Review
- Circadian Rhythms of Clock Genes After Transplantation of Mesenchymal Stem Cells with Type 2 Diabetes Mellitus.International journal of molecular sciences · 2024Article
- Inceptor binds to and directs insulin towards lysosomal degradation in β cells.Nature metabolism · 2024Article
- Supragel-mediated efficient generation of pancreatic progenitor clusters and functional glucose-responsive islet-like clusters.Bioactive materials · 2024Article
- Role of cyclic guanosine monophosphate-adenosine monophosphate synthase-stimulator of interferon genes pathway in diabetes and its complications.World journal of diabetes · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetes mellitus is a metabolic disorder that affects more than 460 million people worldwide. Type 1 diabetes (T1D) is caused by autoimmune destruction of β-cells, whereas type 2 diabetes (T2D) is caused by a hostile metabolic environment that leads to β-cell exhaustion and dysfunction. Currently, first-line medications treat the symptomatic insulin resistance and hyperglycaemia, but do not prevent the progressive decline of β-cell mass and function. Thus, advanced therapies need to be developed that either protect or regenerate endogenous β-cell mass early in disease progression or replace lost β-cells with stem cell-derived β-like cells or engineered islet-like clusters. In this Review, we discuss the state of the art of stem cell differentiation and islet engineering, reflect on current and future challenges in the area and highlight the potential for cell replacement therapies, disease modelling and drug development using these cells. These efforts in stem cell and regenerative medicine will lay the foundations for future biomedical breakthroughs and potentially curative treatments for diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.